Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea Eye Treatment

Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea Eye Treatment...…

Regeneron wins approval for rare immune disease therapy pozelimab

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Pharmaceuticals Veopoz Gets FDA Approval for Adults, Children

Regeneron Pharmaceuticals' Veopoz Gets FDA Approval for Adults, Children...…

Regeneron gets FDA green light on first treatment for life-threatening immune disease

Regeneron Pharmaceuticals Inc. REGN said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease,…

Regeneron Pharma: EMA To Review MAA For Odronextamab

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced the European Medicines Agency has accepted for review the Marketing Authorization Application…

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European…

18 Analysts Have This to Say About Regeneron Pharmaceuticals

Latest Ratings for REGN DateFirmActionFromTo Feb 2022Truist SecuritiesMaintainsBuy Feb 2022OppenheimerMaintainsOutperform Feb 2022Morgan StanleyMaintainsEqual-Weight View More…

AbTherx, Inc.: AbTherx Appoints Gavin Thurston, PhD, as Scientific Advisor

Former Regeneron Oncology Leader Joins AbTherx to Advance its Antibody Discovery PlatformMOUNTAIN VIEW, CA / ACCESSWIRE / August 16, 2023…

Regeneron could see share price bounce with potential approvals

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 673.017$

Bassler, Bonnie L. - Aufsichtsrat - Tag der Transaktion: 2023-08-10...…

Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies

Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for…

Baird downgrades Decibel to neutral to reflect Regeneron takeover

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AKTIONÄR-Top-Tipp Regeneron schlägt zu: Übernahme – Aktie schießt über 80 Prozent hoch

Ein smarter Kauf – zur Erweiterung des Pipeline-Portfolios im Bereich der Gentherapie übernimmt der amerikanische Antikörperspezialist Regeneron Pharmaceuticals das Biotech-Ünternehmen…

Decibel Therapeutics Stock Soars on Acquisition Deal - The Details

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has agreed to acquire Decibel Therapeutics Inc (NASDAQ: DBTX) at $4.00 per share with an additional contingent value…

Decibel Therapeutics Shares Surge on Regeneron Acquisition

Decibel Therapeutics Shares Surge on Regeneron Acquisition...…

Regeneron to acquire gene therapy developer Decibel for $4 per share

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron buying small cap Decibel Therapeutics for $4 a share

Regeneron Pharmaceuticals Inc. REGN said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, a 43% premium…

Regeneron To Acquire Decibel Therapeutics

Regeneron To Acquire Decibel Therapeutics...…

Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for…

Regeneron halts enrollment in prostate cancer trial following two deaths

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline

Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea,…

Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended…

Regeneron’s stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenue

Shares of Regeneron Pharmaceuticals Inc. REGN climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company…

Regenerons stock rallies after profit, revenue rise above expectations, amid a jump in collaboration

Shares of Regeneron Pharmaceuticals Inc. climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company…

UPDATE 2-Regeneron expects FDA decision on high-dose eye drug this year, shares jump

..., adds analyst comment in paragraph 4) Aug 3 (Reuters) - Regeneron......…

Regeneron Pharma beats quarterly profit estimates

...Aug 3 (Reuters) - Regeneron Pharmaceuticals Inc beat Wall Street......…

Regeneron Pharmaceuticals: Kursziel gekürzt

New York (www.aktiencheck.de) - Rating-Update: Yatin Suneja, Analyst von Guggenheim Securities, stuft die Aktie von Regeneron Pharmaceuticals (ISIN: US75886F1075, WKN:…

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for…

Regeneron Pharmaceuticals: Der Einstieg könnte sich langfristig lohnen - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von "Der Aktionär": Jürgen Dreifürst vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

AKTIONÄR-Tipp: Anleger sollten sich bei diesem Bayer-Partner auf die Lauer legen

Die größten Risiken bei Biotech- und Pharmaunternehmen bestehen oft in der Nicht-Zulassung eines Medikaments seitens der Food and Drug Administration…

Is Regeneron Stock a Buy After a Regulatory Blow?

Dont write this companys eulogy too fast....…

Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?

Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept…

Regeneron Pharmaceuticals: Kurszielsenkung

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Die Analysten von Truist belassen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol:…

Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023

TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…

Why Regeneron Pharmaceuticals Stock Dipped This Week

A key regulatory setback is weighing on the biotechs stock....…

The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks

Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog....…

dpa-AFX ProFeed